Skip to main content
. 2020 Jun 15;18:91. doi: 10.1186/s12951-020-00642-1

Fig. 6.

Fig. 6

In vivo antitumor efficacy of DOX-HMONs@GOQDs. a Growth curves of 4T1 tumors in each group; b photographs of tumors at the end of each treatment; c changes in the body weights of the mice over the treatment period; d haemotoxylin and eosin (H&E) staining in the normal tissue group (the control) and the DOX-HMONs@GOQDs group